SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 118.27 |
| Enterprise Value ($M) | 76.47 |
| Book Value ($M) | 38.41 |
| Book Value / Share | 0.60 |
| Price / Book | 3.08 |
| NCAV ($M) | 36.89 |
| NCAV / Share | 0.57 |
| Price / NCAV | 3.21 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.94 |
| Return on Assets (ROA) | -0.54 |
| Return on Equity (ROE) | -0.59 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.41 |
| Current Ratio | 6.41 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 43.79 |
| Assets | 45.32 |
| Liabilities | 6.90 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.01 |
| Operating Income | -39.27 |
| Net Income | -36.90 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -34.88 |
| Cash from Investing | -0.02 |
| Cash from Financing | 28.82 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | New Enterprise Associates 10 L P | 6.20 | -15.12 | |
| 13G/A | Artal International S.C.A. | 13.30 | 30.66 | |
| 13G/A | Biotechnology Value Fund L P | 14.80 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 304,117 | 649,171 | 46.85 | |
| 599,161 | 179,324 | 334.12 | |
| 650,768 | 282,692 | 230.20 | |
| 494,548 | 232,637 | 212.58 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| FULC – Fulcrum Therapeutics, Inc. | GANX – Gain Therapeutics, Inc. |
| GHRS – GH Research PLC | GRTX – Galera Therapeutics, Inc. |
| HCWB – HCW Biologics Inc. |